

BAB V

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan dari literature review pada 17 artikel ilmiah terkait efektivitas dan keamanan penggunaan Dapagliflozine pada pasien DM dengan komplikasi yang dilaksanakan mulai dari bulan Mei 2020 – Juli 2020 dapat disimpulkan bahwa:

1. Penggunaan Dapagliflozin efektif digunakan sebagai terapi tambahan untuk pasien Diabetes Melitus Tipe 2 (gula darah tidak terkontrol) dan obesitas dengan komplikasi kardiovaskular, dan gagal ginjal kronik.
2. Penggunaan Dapagliflozin aman digunakan sebagai terapi tambahan untuk pasien Diabetes Melitus Tipe 2 (gula darah tidak terkontrol) dan obesitas dengan komplikasi kardiovaskular, dan gagal ginjal kronik. Efek samping yang perlu diwaspadai selama penggunaan Dapagliflozin adalah Diabetes Ketoasidosis, Infeksi Saluran Kemih, dan Infeksi Genital.

5.2 Saran

1. Perlu dilaksanakan penelitian lebih lanjut untuk mengetahui faktor resiko yang dapat memicu kejadian diabetes ketoasidosis, infeksi saluran kemih, dan infeksi genital. Informasi tersebut dapat menjadi bekal penting bagi Dokter dan Farmasi dalam monitoring terapi Dapagliflozin.
2. Perlu dilaksanakan penelitian lebih lanjut untuk mengetahui efek penggunaan Dapagliflozin terhadap profil lipid untuk semakin

memperkuat rekomendasi penggunaan pada pasien DM dengan resiko ASCVD tinggi.

3. Perlu dilaksanakan kajian literature dengan memperluas database yang digunakan sehingga artikel ilmiah yang digunakan dapat semakin banyak.
4. Perlu dilaksanakan meta analisa untuk melihat signifikansi hasil dari beberapa penelitian dengan karakteristik maupun luaran hasil yang sama untuk mendapatkan kesimpulan lebih objektif mengenai profil efektivitas dan keamanan penggunaan Dapagliflozin.

DAFTAR PUSTAKA

- Amandari, I.G. 2018, SGLT-2 Inhibitor. Pilihan Terapi baru Untuk Penderita DM Tipe 2, *Hang Tuah Medical Journal*, **16(1)**: 28-36.
- American Diabetes Association (ADA). 2018, *Standard medical care in diabetes 2018*. Riddle MC, ed. *Diabetes Care*, **41(1)**:13-27.
- American Diabetes Association (ADA). 2020, *Standard Medical Care in Diabetes-2020 Abridged for Primary Care Provider*. *Diabetes Care*, **38(1)**: 1-29.
- Anggraini, G. 2015. Kajian Pustaka (Literature Review). Diakses pada 05 Mei 2020,
<https://www.academia.edu/11500074/Kajian.Pustaka.literature.review> .
- Arshed, N. and Danson, M. 2015, 'The Literature Review', in P.K. McBride., *Research Methods for Business & Management*, 2nd ed., Goodfellow, Oxford, pp 31-34.
- Berkat., Saraswati, L.D. dan Muniroh, M. 2018, *Jurnal Kesehatan Masyarakat*, Faktor-faktor yang Berhubungan dengan Kadar Gula Darah pada Penderita Diabetes Tipe 2 di RSUD K.R.M.T Wongsonegoro Semarang, **6(1)**: 200-206.
- Bolinder, J., Ljunggren, O., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A., Sugg, J. and Parikh, S. 2012, Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin, *Journal of Clinical Endocrinology Metabolism*, **97(3)**:1020 –1031.
- Clegg, L.E., Heerspink, H.J.L., Penland, R.C., Tang, W., Boulton, D.W., Bachina, S., Fox, R.D., Thuresson, M., Mentz, R.J., Hernandez, A.F. and Holman, R.R. 2019, Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL, *Diabetes Care*, 1-9.
- Davies MJ, D'Alessio DA, Fradkin J., Kernan, N.W., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D.J. and Buse, J.B. 2018, Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the

European Association for the Study of Diabetes (EASD). *Diabetologia*, Diakses pada 5 Oktober 2018, <https://doi.org/10.1007/s00125-018-4729-5>.

- Decroli, E. dan Kam, A. (eds). 2019, *Diabetes Melitus Tipe 2*, Pusat Penerbitan Bagian Ilmu Penyakit Dalam, Padang.
- Dekkers, C.C.J., Petrykiv, S., Laverman, G., Cherney, D.Z., Gansevoort, R.T. and Heerspink, H.J.L. 2018, Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers, *Diabetes, Obesity and Metabolism*, 1-16.
- Fadini, G.P., Solini, A., Manca, M.L., Penno, G., Gatti, A., Anichini, R., Prato, S.D. and Avogaro, A. 2019, Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study, *Diabetes, Obesity and Metabolism*, 1-22.
- Fatimah, R.N. 2015, Diabetes Melitus Tipe 2, *Jurnal Majority*, **4(5)**: 93-101.
- Fioretto, P., Zambon, A., Rossato, M., Busetto. and Vettor, R. 2015, SGLT2 Inhibitors and the Diabetic Kidney, *Diabetes Care*, **39(2)**:S165–S171.
- Fioretto, P., Prato, S.D., Buse, J.B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A.M., Sjostrom, C.D. and Sartipy, P. 2018, ‘Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The Derive Study’, Department of Medicine, *Endocrine Society 2018 annual conference* (ENDO 2018), Chicago, pp 1-28.
- Geerlings, S., Fonseca, V., Diaz, D.C., List, J. and Parikh, S. 2014, Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria, *Diabetes Research and Clinical Practice*, **103** : 373-381.
- Ghani, M.A., Migahid, O., Megahed, A., Singh, R., Fawas, M., DeFronzo, R.A. and Jayyousi, A. 2019, Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study, *Diabetes, Obesity and Metabolism*, 1-15.
- Henry, R.R., Strange, P., Zhou, R., Pettus, J., Shi, L., Zhuplatov, S.B., Mansfield, T., Klein, D. and Katz, A. 2018, Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A

- Randomized Controlled Trial, *Diabetes Technology & Therapeutic*, **20(11)**: 1-10.
- Heerspink, H.J.L., Johnsson, E., Nilsson, G.I., Cain, V.A. dan Sjostrom, C.D. 2016, Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers, *Diabetes, Obesity and Metabolism*, **18**: 590–597.
- International Diabetes Federation. 2019, *IDF Diabetes Atlas*, 9th ed., International Diabetes Federation.
- Kalumpiu, J.V. 2019, Dapagliflozin : manfaat dan risiko pada diabetes melitus tipe 2, *Jurnal Biomedika dan Kesehatan*, **2(2)**: 81-89.
- Kato, K., Suzuki, K., Aoki, C., Sagara, C.A., Sagara, M., Niitani, T., Wakamatsu., Yanagi, K. and Aso, Y. 2017, The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: A randomized, crossover, controlled clinical trial, *Expert Opinion on Pharmacotherapy*, 1-29.
- Kementerian Kesehatan Republik Indonesia, 2011, *Pedoman Interpretasi Data Klinik*, Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia, 2018. *Hasil Utama Hasil RISKEDAS 2018*, Indonesia.
- Lam, C.S.P., Chandramouli, C., Ahooja, V. and Verma, S. 2019, SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet. Needs, and Therapeutic Prospects, *Journal of the American Heart Association*, 1-12.
- Leiter, L.A., Cefalu, W.T., de Bruin, T.W.A., Xu, J., Parikh, S., Johnsson, E, and Nilsson, I.G. 2016, Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease, *Diabetes, Obesity and Metabolism*, 1-9.
- Ley, H.S., Schulze, M.B., Hivert, M.F., Meigs, J.B. and Hu, F.B. 2015, 'Risk Factors for Type 2 Diabetes' in Cissell, M.A., *Diabetes in America*, 3rd ed., Defense Intelligence Agency, America, pp 1-37.
- Loutradis, C., papadopoulou, E., Theodorakopoulou, M., Karagiannis, A. and Sarafidis, P. 2019, The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio and nephroprotection, *Future Medicinal Chemistry*, **11(11)**: 1285–1303.

- Made, P. 2019, Terapi Diabetes dengan SGLT-2 Inhibitor, *Medical Department*, PT Kalbe Farma Tbk Jakarta, Indonesia, **46(6)**: 452-456.
- Marzali, A. 2016, Menulis Kajian Literatur, *Jurnal Etnosia*, **1(2)**: 27-36.
- McGurnaghan, S.J., Brierly, L., Caparrotta, T.M., McKeigue, P.M., Blackbourn, L.A.K., Wild, S.H., Leese, G.P., McCrimmon, R.J., McKnight, J.A., Pearson, E.R., Petrie, J.R., Sattar, N. and Colhoun, H.M. 2018, The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study, *Diabetologia*, 1-12.
- McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Kober, L., Kosiborod, M.N., Martinez, F.A., Ponikowski, P., Sabatine, M.S., Asnand, I.S., Belohlavek, J., Bohm, M., Chiang, C.E., Chopra, V.K., Boer, R.A.D., Desai, A.S., Diez, M., Drozd, J., Dukat, A., Ge, J., Howlett, J.G., Katova, T., Kitakaze, M., Ljungman, C.E.A., Merkely, B., Nicolau, J.C., Meara, O.E., Petrie, M.C., Vinh, P.N., Schou, M., Tereshchenko, S., Verma, S., Held, C., DeMets, D.L., Docherty, K.F., Jhund, P.S., Bengtsson, O., Sjostrand, C. and Langkilde, A.M. 2019, Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, *The new england journal of medicine*, 1-13.
- Morris, D. 2017. The SGLT2 inhibitors – where are we now?. *Journal of Diabetes Nursing*. 21(5): 162-165.
- Mosenzon, O., Wiviott, S.D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E.L., Murphy, S.A., Heerspink, P.H., Zelniker, T.A., Dwyer, J.P., Bhatt, D.L., Leiter, L.A., McGuire, D.K., Wilding, J.P.H., Kato, E.T., Nilsson, I.M.A.G., Fredriksson, M., Johansson, P.A., Langkilde, A.M., Sabatine, M.A. and Raz, I. 2019, Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial, *Lancet Diabetes Endocrino*, **7**: 606-617.
- Murti, B. 2013. Pengantar Evidence Based Medicine. Diakses pada 24 April 2020, https://www.academia.edu/29813384/Evidence_Based_Medicine_PENGANTAR_EVIDENCE-BASED_MEDICINE.
- Nassif, M.E. 2019, Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial, *Circulation*, **140**: 1-14.
- Nielsen, R., Moller, N., Gormsen, L.C., Tolbod, L.P., Hansson, N.H., Sorensen, J., Harms, H.J., Frokier, J., Eiskjaer, H., Jespersen, N.R.,

- Mellekjaer, S., Lassen, T.R., Pryds, K., Botker, H.E. and Wiggers, H. 2019, Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients, *Circulation*, **139**: 2129-2141.
- Norhammar, A., Bodegard, J., Nystrom, T., Thuresson, M., Nathanson, D. dan Eriksson, J.W. 2019, Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study, *Diabetes, Obesity and Metabolism*, **21**:1136–1145.
- Perkumpulan endokrinologi Indonesia, 2015. *Konsensus Pengolahan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2015*. PERKENI, Indonesia.
- Petrykiv, S.I., Laverman, G.D., de Zeeuw, D. Heerspink. dan H.J.L. 2017, The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients, *Diabetes, Obesity and Metabolism*, 1-22.
- Phrommintikul, A., Wongcharoen, W., Kumfu, S., Jaiwongkam, T., Gunaparn, S., Chattipakorn, S. dan Chattipakorn, N. 2019, Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study, *British Journal of Clinical Pharmacology*, **85**:1337–1347.
- Plows, J.F., Stanley, J.L., Baker, P.N., Reynolds, C.M. and Vickers, M.H. 2018, The Pathophysiology of Gestational Diabetes Mellitus, *International Journal of Molecular Sciences*. Diakses pada 28 Oktober 2018, <https://doi.org/10.3390/ijms19113342>.
- Pollock, C., Stefansson, B., Reyner, D., Rossing, P., Sjostrom, C.D., Wheeler, D.C., Langkilde, A.M. and Heerspink, H.J.L. 2019, Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial, *Lancet Diabetes Endocrinol*, 1-13
- Putradana, A. 2016, 'Konsep Evidence Based Practice', *Tesis*, Magister Keperawatan, Fakultas Kedokteran Universitas, Diponegoro.
- Saraswati, M. R. 2016. Bali Endocrinology Update (BEU XIII) Endocrinology and Beyond. Denpasar: PT. Percetakan Bali.

- Satirapoj, B. 2017, Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects, *Kidney Disease*, **3**: 24-32.
- Shao, S.C., Chang, K.C., Hung, M.J., Yang, N.I., Chan, Y.Y., Chen, H.Y., Yang, Y.H.K. and Lai, E.C.C. 2019, Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study, *Cardiovascular Diabetology*, **18**:1-15.
- Solini, A., Seghieri, M., Giannini, L., Biancalana, E., Parolini, F., Rossi, C., Dardano, A., Taddei, S., Ghidoni, L. and Bruno, R.M. 2019, The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature, *Journal Clinical Endocrinology Metabolism*, **104(10)**:4253–4263.
- Steglitz, J., Warnick, J.L., Hoffman, S.A., Johnston, W. dan Spring, B. 2015, Evidence Based Practice, *International Encyclopedia of the Social & Behavioral Sciences*, **8**: 332-338.
- Sugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Tanaka, M., Nishimura, H., Suzuki, T., Miyamoto, F., Kajiwara, K. and Jinnouchi, T. 2018, Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus, *Journal of clinical medicine*, **10(6)**:466-477.
- Tjay, R. 2007, *OBAT-OBAT PENTING Khasiat Penggunaan dan Efek-Efek sampingnya*, 6th ed., PT Elex Media Komputindo Kelompok Gramedia, Jakarta.
- Tumbelaka, A.R. 2002, Evidence Based Medicine (EBM), *Sari Pediatri*, **3(4)**: 247-248.
- Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M.G., Zelniker, T.A., Kuder, J.F., Murphy, S.A., Bhatt, D.L., Leiter, L.A., McGuire, J.P.H., Wilding, J.P.H., Ruff, C.T., Nilsson, I.A.M., Fredriksson, M., Johansson, P.A., Langkilde, A.M. and Sabatine, M.S. 2018, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, *The new england journal of medicine*, **380**:347-57.
- Yahya, N. dan Mellyora, A.(Ed.). 2018, *Hidup Sehat dengan Diabetes*, PT Tiga Serangkai Pustaka Mandiri, Solo.